Gd eob bpta primovist

MR studies were performed with 2 1.5T MR tomographs: a Magnetom Symphony (Siemens, Erlangen, Germany) and Magnetom Aera (Siemens). The MRI images were acquired before and after an intravenous (IV) contrast agent (CA) injection.
In this study, a radiomics features extraction was made on volumetric interpolated breath-hold examination (VIBE) T1-weighted SPAIR with controlled respiration used to acquire images after IV CA injection with a liver-specific CA (0.1 mL/kg of Gd-EOB-BPTA—Primovist, Bayer Schering Pharma, Berlin, Germany). The VIBE T1-W sequence was acquired with 2 different flip angles (10 and 30 degrees). A power injector (Spectris Solaris^® EP MR, MEDRAD Inc., Indianola, IA, USA) was used to administrate the CA at an infusion rate of 2 mL/s, as descripted in our previous studies [26 (link),27 (link)]. Table 2 reports MR Sequence parameters.

A 1.5 T Magnetom Symphony scanner (Siemens, Erlangen, Germany) and a 1.5 T Magnetom Aera scanner (Siemens) equipped with an 8-element body and phased array coils were used for image acquisition of MR, including sequences obtained before and after intravenous (IV) injection of contrast medium. Volumetric interpolated T1-weighted SPAIR (VIBE) with controlled respiration was used to acquire images after IV injection of contrast agent (CA) with a liver-specific CA (0.1 mL/kg of Gd-EOB-BPTA, Primovist, Bayer Schering Pharma, Berlin, Germany). A power injector (Spectris Solaris^® EP MR, MEDRAD, Inc., Indianola, IA, USA) was used to deliver contrast agent at an infusion rate of 2 mL/s, and VIBE T1-w images were acquired in four different phases: arterial phase (35 s delay), portal venous phase (90 s), transition phase (120 s) and hepatobiliary excretion phase (20 min).
The study protocol is reported in Table 1.